GlobalData on MSN2d
Gilead and MSD to advance once-weekly HIV treatment to Phase III
The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Success of long-lasting HIV drug hinges on pricing
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
News Medical2d
Affordability and supply remain critical to the success of long-lasting HIV drug
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Future Market Insights3d
Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to be valued US$ 62.37 Billion by 2033, at a CAGR of 6%
The 1) Market is expected to reach a substantial USD 34.83 billion by 2033, according to a new report. This reflects a ...
Gilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir Combination In HIV Treatment
Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...
Business Wire4d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Science Daily4d
HIV and AIDS News
25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However ... 2024 — Metformin, a drug used to treat type 2 diabetes, could help deplete the viral ...
The American Journal of Managed Care8d
Financial Burdens of HIV Treatment and HCRU
Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV ...
FiercePharma8d
With Gilead coming fast, GSK bolsters case for long-acting HIV PrEP drug Apretude
With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...
Truepill’s Sid Viswanathan Is Back With A New Pharmacy Startup Focused On HIV
Alchemy, which sets up pharmacies in community clinics, said that it had raised $31 million from Andreessen Horowitz and ...
Hosted on MSN13d
Gilead's HIV Prevention Treatment Lenacapavir Shows Potential
Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for the ...
Daily Express15d
Single pill could save lives with revolutionary hypertension treatment, new research finds
The groundbreaking milestone appears to lie in a pill that combines telmisartan, amlodipine, and indapamide, all of which are currently used as treatment separately for hypertension. The research ...